NCT02313012 - Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 5, 2015

Primary Completion Date

May 3, 2016

Study Completion Date

May 3, 2016

Conditions

Neoplasm Metastasis

Interventions

DRUG

CC-90003

CC-90003 PO once daily

Trial Locations (5)

Peter MacCallum Cancer Centre, Melbourne

Levine Cancer Institute, Charlotte

Sarah Cannon Cancer Center, Nashville

Cedars Sinai Medical Center, Inflammatory Bowel Disease Center, Los Angeles

Smilow Cancer Center, New Haven